CO - CO STOCK NEWS

Global Cord Blood Corporation (NYSE: CO) announced its 2021 annual general meeting (AGM) to be held on December 7, 2021, at 9:00 p.m. Hong Kong Time. Shareholders on record as of October 25, 2021, will be eligible to vote. The Company emphasizes compliance with COVID-19 regulations, requiring temperature checks and face coverings for attendees. They have also filed their annual report with the SEC, which is accessible online. Global Cord Blood Corporation is noted as the largest umbilical cord blood banking operator in China.

Global Cord Blood Corporation (NYSE: CO) reported a revenue increase of 12.2% YoY to RMB315.2 million ($48.8 million) for Q1 2022, driven by a rise in new subscribers and processing fees. The company added 19,673 new subscribers, bringing the total to 920,195. Gross profit rose 12.6% YoY to RMB267.3 million ($41.4 million), with net income up 3.0% YoY to RMB136.4 million ($21.1 million). Despite positive results, the company expressed caution regarding potential impacts from COVID-19 lockdowns and declining newborn trends.

Global Cord Blood Corporation (NYSE: CO), a leading provider of cord blood services in China, will release its financial results for the first quarter of fiscal 2022 on August 30, 2021, after market close. A conference call to discuss the results will occur on August 31, 2021, at 8:00 a.m. ET, accessible via the Company's IR website. The Company is notable for being the first and largest umbilical cord blood banking operator in China, holding multiple licenses and offering comprehensive services such as collection and storage.

Global Cord Blood Corporation (NYSE: CO), China's leading provider of cord blood collection and related services, has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. This report includes audited financial statements for the fiscal year ended March 31, 2021. Investors can access the Form 20-F on the SEC's website or the Investor Relations section of the Company's website.

GCBC remains the largest umbilical cord blood banking operator in China, offering comprehensive cord blood services.

Global Cord Blood Corporation (NYSE: CO) reported its Q4 fiscal 2021 results, showing a 0.8% YoY increase in revenues to RMB302.3 million ($46.1 million). The company added 19,367 new subscribers, raising its total subscriber base to 901,437. Net income attributable to shareholders rose 31.7% YoY to RMB127.7 million ($19.5 million), largely due to a reduced fair value loss in equity securities. However, full-year revenues fell 5.1% YoY to RMB1,159.6 million ($177.0 million). Operating cash flow surged 134.6% YoY to RMB211.1 million ($32.2 million).

Global Cord Blood Corporation (NYSE: CO) announced plans to release unaudited financial results for Q4 and full year fiscal 2021 on June 28, 2021, post U.S. market close. A conference call is scheduled for June 29, 2021, at 8:00 a.m. ET, to discuss the financial performance and recent developments, followed by a Q&A session. Supplemental financial data will be accessible on the company’s website after June 28, 2021. Global Cord Blood Corporation is China's largest umbilical cord blood banking operator, providing various stem cell services.

Global Cord Blood Corporation (NYSE: CO) announced the formation of a special committee to evaluate a non-binding acquisition proposal from Alternate Ocean Investment Company, which offers to buy the company at US$5.00 per share. The Board has not yet decided on the proposal, stressing the need for due diligence and regulatory approvals. The committee, led by independent directors, is assessing the offer, but no definitive agreements or guarantees have been established regarding the transaction.

Global Cord Blood Corporation (NYSE: CO) received a non-binding acquisition proposal from Alternate Ocean Investment Company Limited to purchase all outstanding shares at US$5.00 per share. The Board of Directors will carefully evaluate this unsolicited offer while fulfilling its fiduciary duties. Shareholders need not take any action at this time. GCBC is a leading provider of cord blood services in China, with extensive geographical coverage and multiple licenses.

Global Cord Blood Corporation (NYSE: CO) reported a 13.1% decline in Q3 revenues, totaling RMB290.8 million ($44.6 million). Despite a strong subscriber base of 882,982, new subscriber growth fell by 23.9% to 17,802. Gross profit also decreased 13.1% YoY to RMB245.9 million ($37.7 million), maintaining a gross margin of 84.6%. Operating income declined by 18.9% to RMB124.0 million ($19.0 million). Net income attributable to shareholders fell 19.6% to RMB116.6 million ($17.9 million).